NCT00525616

Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid

Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: University Hospital, Rouen · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to assess that it will be possible to control with a single cycle of rituximab patient with bullous pemphigoid.

Detailed description

The objective of this study is to assess the efficacy and tolerance of a single cycle of rituximab in control of bullous pemphigoid. the main objects are : 1. to assess that a single cycle of rituximab is able to control patient with corticosteroid-dependent bullous pemphigoid, 2. to avoid the use of corticosteroid in long time, 3. to evaluate duration of control disease and side effect with a single cycle of rituximab.

Conditions

• Bullous Pemphigoid

Interventions

Type	Name	Description
DRUG	Mabthera	Two IV perfusions of 1000mg at 15 days intervals

Timeline

• Start date: 2008-12-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2007-09-06
• Last updated: 2026-04-16

Locations

1 site across 1 country: France